Quest Diagnostics (DGX)
162.28
-0.36 (-0.22%)
At close: Feb 10, 2025, 10:19 AM
undefined% (undefined)
| Bid | 162.06 |
| Market Cap | 18.11B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 7.69 |
| PE Ratio (ttm) | 21.1 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 162.33 |
| Volume | 73,646 |
| Avg. Volume (20D) | 903,361 |
| Open | 162.34 |
| Previous Close | 162.64 |
| Day's Range | 161.72 - 163.35 |
| 52-Week Range | 123.30 - 167.08 |
| Beta | undefined |
About DGX
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPat...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Dec 17, 1996
Employees 50,000
Stock Exchange NYSE
Ticker Symbol DGX
Website https://www.questdiagnostics.com
Analyst Forecast
According to 13 analyst ratings, the average rating for DGX stock is "Hold." The 12-month stock price forecast is $180, which is an increase of 10.92% from the latest price.
Buy 53.85%
Hold 46.15%
Sell 0.00%
Next Earnings Release
Quest Diagnostics is scheduled to release its earnings on Apr 22, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+5.62%
Quest Diagnostics shares are trading higher follow...
Unlock content with
Pro Subscription
3 months ago
+6.85%
Quest Diagnostics shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.
